This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Cryoport, Inc. ("Company"), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizaions, vaccine manufacturers and reproductive medicine, announced that it is co-sponsoring the Alliance for Regenerative Medicine 3rd Annual REGENMED Investor Day, to be held March 25, 2015 at the Metropolitan Club in New York City.
The one-day, high impact program provides institutional, strategic and venture investors with unique insight into regenerative medicine and advanced therapy-based treatments and tools. Clinical and commercial experts will be on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how advanced therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. The event will also feature discussions with key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from
across the globe.
"We are excited to be an industry sponsor to this annual event organized by the Alliance for Regenerative Medicine," stated Jerrell Shelton, Chief Executive Officer of Cryoport. "The participating and presenting companies play a vital role in the advancement of many new and potentially life-saving cell-based therapies. Cryoport offers validated and best-in-class cryogenic logistics solutions to support these important new developments in regenerative medicine. For example, we can support their logistics needs from early clinical trial distribution to commercialization strategies for allogeneic and autologous cell-based immunotherapies."
According to a 2015 State of the Industry Briefing for regenerative medicine and advanced therapies given by ARM, there are 375 clinical trials in various stages of development and over 60 approved products in the space. A recent industry report states that the global market for regenerative medicine is expected to grow at a compound annual growth rate of 20% from 2014 to 2019. Cryoport is well positioned to become the logistics partner of choice in this growing market.
>> For more information, click here
